ACIP Recommends Use of Merck’s ENFLONSIA for Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
ENFLONSIA is the first and only RSV preventive option for administration to infants using the same dose regardless of weight. Ordering will begin in July, with shipments delivered before the start of the 2025-2026 RSV season
